Revenue decreased 7.6%
Revenue changed -7.6% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Revenue changed -7.6% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Stock-based compensation changed -25.2% from the comparable as-filed period.
Net income changed +108.7% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
Selling, general & administrative changed -7.7% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Gross profit changed -6.0% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Research & development changed -5.8% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.